Coronary CT angiography (CCTA) detected coronary artery disease in more than half of men with erectile dysfunction, according to research presented July 10 at the Society of Cardiovascular Computed Tomography (SCCT) meeting. 

The finding is from a retrospective analysis among 63 asymptomatic men (no chest pain) with vasculogenic erectile dysfunction (ED) referred for CCTA for cardiovascular risk stratification between 2019 and 2025, noted presenter Olga Brezinov, MD, of McGill University in Montreal, and colleagues. 

“While previous studies have established the correlation between [erectile dysfunction] and cardiovascular events, less is known about the characteristics and severity of [coronary artery disease] in ED patients assessed using CCTA,” the group wrote. 

Erectile dysfunction caused by vascular problems is associated with a higher risk of coronary artery disease (CAD) because the two conditions share underlying mechanisms, the authors explained. Vasculogenic ED, unlike forms caused by hormonal, neurological, psychological, or medication-related factors, stems from impaired blood flow. 

For the study, the researchers collected demographics, cardiovascular risk factors, lab results, medications, and penile Doppler ultrasound findings for 63 patients from electronic medical records. CCTA was used to calculate coronary artery calcium (CAC) scores and grade the presence and severity of CAD, with patients split into two groups: CAD or no-CAD. 

According to the results, arterial ED was present in 43 patients (69%), venous ED in five (8%), and mixed ED in 14 (23%). CAD was identified in 35 patients (56%). Nine patients (26%) had lesions with at least 50% stenosis. The mean calcium score in the CAD group was 393 Agatston units. Notably, three (9%) patients with non-obstructive CAD had a calcium score of zero, and hypertension (Odd ratio [OR] 3.8; p = 0.04) and age (OR 1.1 per year; p = 0.03) were independent predictors of CAD, the researchers reported. 

Further, patients with CAD underwent more intensive management and longer follow-up than those without CAD (350 vs 183 days; p = 0.016), the authors noted. In the CAD group, 20 patients (57%) started or intensified statin therapy, 10 (29%) started aspirin, 13 (28%) underwent additional noninvasive imaging, two (6%) had invasive coronary angiography, and one had a myocardial infarction. No events or therapy changes occurred in the no-CAD group. 

"CCTA findings led to treatment optimization and closer clinical surveillance," the authors concluded.